Whitefort Capital Increases Stake to 8.1% with $8.5M in Recent Purchases
ABUS sits 47% above its 52-week low of $2.94.
Summary
Institutional investor Whitefort Capital has increased its stake in Arbutus Biopharma to 8.1% by purchasing approximately $8.5 million worth of shares in the open market.
Key Events · Ownership and Investor Activity · ABUS
-
Increased Ownership Stake
Whitefort Capital Master Fund, LP and its affiliates now beneficially own 15,794,261 shares, representing 8.1% of Arbutus Biopharma's outstanding common stock.
-
Significant Open Market Purchases
The filing details approximately $8.5 million in common stock purchases made by Whitefort Capital Master Fund, LP in the open market over the past 60 days, with transaction prices ranging from $4.1213 to $4.2500 per share.
-
Follows Major Patent Settlement
This increased investment by an institutional holder comes after Arbutus Biopharma's recent patent settlement with Moderna for up to $2.25 billion, reinforcing positive sentiment around the company's financial future.
Analysis · ABUS · Life Sciences
Whitefort Capital Master Fund, LP, an institutional investor, has increased its beneficial ownership in Arbutus Biopharma Corp to 8.1% through recent open market purchases totaling approximately $8.5 million. This increased stake follows the company's significant patent settlement with Moderna, suggesting continued institutional confidence in the company's outlook and financial strength. The sustained buying activity by a major shareholder indicates a positive long-term view.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $854.2M. The 52-week trading range was $2.94 to $5.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.